Trump is unlikely to end Medicare drug price talks — here's what that means for patients and pharma
Trump could either weaken the negotiations in a way that benefits the pharmaceutical industry, or try to achieve even deeper ...
What a $2 Million Per Dose Gene Therapy Reveals About Drug Pricing
Robin Fields ProPublica is a nonprofit newsroom that investigates abuses of power. Sign up to receive our biggest stories as ...
How Medicare Says It Arrives At ‘Fair’ Prescription Drug Prices
We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...
Medical Marketing & Media1d
RFK Jr. confirmed as HHS Secretary: Here’s how pharma might be impacted
Vaccine policy, Medicare drug negotiations, and a potential DTC advertising ban will all fall under Kennedy’s purview as HHS ...
Here's how Trump's tariffs on China could impact drug pricing and other healthcare costs
While Trump's tariffs could have a broad impact on healthcare prices, it is likely they will not have the devastating result ...
Kaleido Scope2d
The 340B Drug Pricing Program: Are 340B Covered Entities Providing More Services and More Uncompensated Care?
The 340B Drug Pricing Program enacted in 1992 requires pharmaceutical manufacturers participating in the Medicaid program to provide statutorily defined discounts on "covered outpatient drugs" ...
Pharmacy benefit management unicorn Capital Rx hits $3.5 billion in revenue with a different approach to drug pricing as Congress targets middlemen
Healthcare startup Capital Rx seeing revenue surge as Congress seeks to regulate the PBM giants that profit from high drug ...
JD Supra1d
Mintz IRA Update — From the Desk of ML Strategies: The Medicare Drug Price Negotiation Program Under the Second Trump Administration
The start of Donald Trump’s second presidency and Republican control in the 119th Congress raises questions about the future ...
Verona Pharma (NASDAQ:VRNA) Price Target Raised to $72.00
Verona Pharma (NASDAQ:VRNA – Free Report) had its price target hoisted by Canaccord Genuity Group from $44.00 to $72.00 in a research note published on Wednesday,Benzinga reports. They currently have ...
JD Supra1d
Mintz IRA Update — The Future of the Medicare Drug Price Negotiation Program
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...